A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Summary

This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.

Timeline

Start

2021-02-26

Primary completion

2023-03-28

Completion

2023-09-13

Outcome

Met primary endpoint

release “In the Phase 2 ARCHER trial, vonaprument demonstrated significant vision preservation in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA).” annexonbio.com ↗

release “Vonaprument provided statistically significant, time and dose-dependent protection from vision loss as measured by confirmed best corrected visual acuity (BCVA) ≥15-letter loss” annexonbio.com ↗

Publications

• Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ANX007	Unknown	—	Intravitreal

Indications